Patents by Inventor Pankaj Kisan CHATKI
Pankaj Kisan CHATKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240173282Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof including baclofen at concentrations of equal to or more than 2 mg/ml or more. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided.Type: ApplicationFiled: February 9, 2024Publication date: May 30, 2024Applicant: ANI Pharmaceuticals, Inc.Inventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20240131018Abstract: Pharmaceutical compositions suitable for oral administration (such as a tablet or a capsule) are provided, which comprise a therapeutically effective amount of an amorphous solid dispersion of cabozantinib, e.g., for treating a proliferative disorder. Preferably, the amorphous solid dispersion consists of (a) cabozantinib or a pharmaceutically acceptable salt thereof (such as cabozantinib (S)-malate); (b) at least one pharmaceutically acceptable carrier selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), and mixtures thereof; (c) a pore-forming agent; and (d) a plasticizer.Type: ApplicationFiled: November 29, 2023Publication date: April 25, 2024Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20240016771Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: ApplicationFiled: September 26, 2023Publication date: January 18, 2024Applicant: ANI Pharmaceuticals, Inc.Inventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Patent number: 11857524Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: GrantFiled: April 4, 2023Date of Patent: January 2, 2024Assignee: ANI Pharmaceuticals, Inc.Inventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20230285341Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: ApplicationFiled: April 4, 2023Publication date: September 14, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20230270736Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: May 5, 2023Publication date: August 31, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Patent number: 11696906Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: GrantFiled: December 22, 2022Date of Patent: July 11, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Patent number: 11679105Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: GrantFiled: February 10, 2023Date of Patent: June 20, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore
-
Publication number: 20230181561Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: February 10, 2023Publication date: June 15, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20230139109Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: ApplicationFiled: December 22, 2022Publication date: May 4, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Patent number: 11590122Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: GrantFiled: February 16, 2022Date of Patent: February 28, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore
-
Patent number: 11564898Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: GrantFiled: September 20, 2022Date of Patent: January 31, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20230028957Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: ApplicationFiled: September 20, 2022Publication date: January 26, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20220387418Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: August 10, 2022Publication date: December 8, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20220362235Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: July 18, 2022Publication date: November 17, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20220347140Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: ApplicationFiled: February 2, 2022Publication date: November 3, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Patent number: 11484518Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: GrantFiled: February 2, 2022Date of Patent: November 1, 2022Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20220280500Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: May 25, 2022Publication date: September 8, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20220265633Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: February 16, 2022Publication date: August 25, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE